Searched for
PIRAMAL PHARMA TARGET PRICE
Sensex rises 254 points, Nifty closes above 24,150; IndiGo, Trent among top gainersIndian stock markets closed higher on Thursday, with Sensex and Nifty extending gains for a fifth consecutive session. Despite a hawkish US...- Stock Radar: Why TMPV is a good long term buy at current levels; stock rallies over 20% in last 3 monthsTata Motors Passenger Vehicles Ltd (TMPV) is showing signs of a comeback, bouncing strongly from multi-year lows around the ₹190-210 suppor...
- Robinhood stock soars despite layoffs – Why Wall Street is bullishRobinhood shares rallied after announcing a 10% workforce reduction, as investors viewed the move as a cost-efficiency strategy. Strong tra...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsFrom a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...
- API prices fall as West Asia tensions ease, boosting Indian pharma sectorPrices for active pharmaceutical ingredients have seen a decline of five to ten percent, thanks to the calming geopolitical climate in West...
- Stock Radar: MRPL bounces back after forming double bottom formation; stock still down 25% from highs – should you buy?Mangalore Refinery and Petrochemicals Ltd stock is showing positive signals. A double bottom formation on daily charts indicates a potentia...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- Zydus Lifesciences shares fall 2% as firm acquires US-based Assertio Holdings for $166 millionZydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Nomura raises Adani Ports share price target by 12%. Here are 3 major reasons whyNomura has raised its target price on Adani Ports and Special Economic Zone to Rs 2,080 from Rs 1,850, while retaining its Buy rating. The ...
- RIL shares jump 6% in 3 days, market cap soars by Rs 1 lakh cr ahead of AGM. Why Morgan Stanley still sees 38% upsideReliance Industries has added over Rs 1 lakh crore in market value in just three trading sessions ahead of its closely watched AGM. Despite...
- Buy, Sell or Hold: RIL remains Morgan Stanley's top pick; remains underweight on Oil IndiaBrokerages remain selective on India's energy sector, favouring companies with strong growth drivers and attractive valuations. Morgan Stan...
- Stock Radar: Nestle India stock gives a breakout from a falling channel trendline; time to buy?Nestle India Ltd has broken out of a falling channel resistance on daily charts, signaling potential for further gains. Experts suggest sho...
- PL Capital cuts Nifty target to 26,449, lists 16 high conviction stock picksAmidst global market turmoil from the Iran-US war and El Nino, PL Capital lowered its Nifty 50 target to 26,449. The brokerage anticipates ...
- 'Not a great environment for Indian market': Harsha Upadhyaya on Iran-US tensions, IT outlook, pharma bet, and where to be cautiousGlobal challenges are impacting Indian stocks. West Asian tensions and rising US inflation create headwinds. Tech sector shifts also affect...
- Market Trading Guide: Allied Blenders among 2 stock recommendations for FridayDomestic markets recovered modestly on easing oil prices and selective buying in banking and pharma stocks. Analysts have recommended Allie...
- AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancerAstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its impo...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Honasa shares jump 6% on Rs 5,500 crore revenue target by FY31. What is Goldman Sachs saying?Honasa Consumer shares surged after the company outlined a revenue target of ₹5,500 crore by FY31. The guidance implies an annual growth ra...
- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
Load More
